Th1 vaccination priming for active immunotherapy

A method for treating an individual susceptible to a disease comprising:

• developing an anti-alloantigen immunity in an individual by administering a priming composition comprising allogeneic activated Th1 memory cells to the individual, wherein the individual's immune system increases the titer of the circulating anti-alloantigen specific Th1 cells, the priming composition administered prophylactically, prior to onset of disease in the individual, the allogeneic Th1 memory cells activated by the cross-linking of CD3 and CD28 surface molecules at the time of formulation and administration, the priming composition comprising allogeneic Th1 memory cells, and cross-linking agents for cross-linking the CD3 and CD28 surface moieties on the Th1 memory cells, wherein the anti-alloantigen immunity is developed in the individual prior to administration of disease-related antigens;
• and
• administering an activating composition comprising allogeneic activated Th1 memory cells and the one or more disease-related antigens to the primed individual, wherein the activating composition is administered at or after the onset of the disease in the individual.